BAY 73-6691 ((R)-BAY 73-6691) 是一种有效的，可透过血脑屏障的选择性 PDE9A 抑制剂。

BAY 73-6691 ((R)-BAY 73-6691) is a potent, brain penetrant, and selective PDE9A inhibitor.

Solid

PDE9A

The BAY 73-6691 dose-dependently alleviates cell viability loss due to Aβ25-35 treatment. It is found that when SH-SY5Y cells are cultured by Aβ25-35, a high degree of cell apoptosis is observed, while additional stimulation with BAY 73-6691 causes attenuation of cell apoptosis. BAY 73-6691 dose-dependently attenuates oxidative stress induced by Aβ25-35, and BAY 73-6691 at 200 μg/mL almost neutralizes Aβ25-35-induced oxidative damage. The BAY 73-6691 attenuates Aβ25-35-induced increase of apoptosis cells. has not independently confirmed the accuracy of these methods. They are for reference only.

BAY 73-6691 dose-dependently improves the acquisition performance in the Aβ 25-35 -injected mice on days 7 to 10 (day 7, F (5,54) =65.153; day 8, F (5,54) =62.340; day 9, F (5,54) =37.529; day 10, F (5,54) =38.624; P<0.001). BAY 73-6691 at 3 mg/kg can almost completely abolish the prolongation of escape-latency on days 9 to 10. BAY 73-6691 dose-dependently elevates the Aβ 25-35 -induced decrease of the dwell time on the 10th day post Aβ 25-35 injection (day 10, F (5,54) =27.360, P<0.001). Results reveal that the Aβ 25-35 injection and BAY 73-6691 treatment cause no influence on the swimming speed. Treatment with BAY 73-6691 does not cause detectable alteration of spatial memory in sham mice. BAY 73-6691 alleviates Aβ 25-35 -induced abnormalities of the above indices. The BAY 73-6

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Li J, et al. Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-β peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimers disease. Brain Res. 2016 Jul 1;1642:327-335.

In Vitro: DMSO : 160 mg/mL (448.52 mM; Need ultrasonic and warming)配制储备液